With about 70 patents, series of fundings, and an innovative product line, primarily to address the prevention and removal of microbial biofilms, finally the 19-year-old company makes it big in the bioscience industry!
Medicure is a pharmaceutical company focused on the development and commercialization of cardiovascular therapeutics for the U.S. market
Medicure's vision is to become a leading cardiovascular pharmaceutical company within the U.S, offering a growing product portfolio of cardiovascular products that improve patients' lives. We have an unwavering focus on delivering safe, efficacious and cost-effective medicines that benefit patients, healthcare providers and shareholders. Our commitment to service, partnership and integrity is what sets us apart.
Medicure was established in 1997, and spent its first decade focused on research and development. In 2008, the company began a transition to focus on its commercial pharmaceutical business. This new direction has provided significant shareholder value with the growth of Aggrastat® (tirofiban hydrochloride) sales, achieving profitability, and the pursuit of development and acquisition opportunities.